{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:46Z","timestamp":1787020846126,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A recent meta-analysis on the active versus expectant management of patent ductus arteriosus in preterm infants, including 10 randomized control trials involving 2035 infants, found that the incidence of death at 36 weeks or moderate to severe bronchopulmonary dysplasia (BPD) and of death was higher in the active treatment group. The accompanying editorial suggested that \u201c\n                    <jats:italic>the use of early routine pharmacologic treatment no longer appears to be justifiable\u201d.<\/jats:italic>\n                    However, this meta-analysis is based on highly heterogeneous studies due to different diagnostic criteria used to define hemodynamically significant PDA, postnatal age at which the echocardiography was performed, pharmacological treatment, high frequency of open label treatment in the placebo\/expectant management group. Moreover, authors did not explain the reduction in mortality that they reported. We concluded that clinical and methodological heterogeneity among studies may not be detected by statistical heterogeneity tests, reducing the interpretability of the results and weakening causal inferences. The high occurrence of open-label treatment indicates the need to perform a per-protocol analysis, which would have been possible if the authors had performed an individual participant data network meta-analysis. Furthermore, the current lack of pathophysiological plausibility suggests caution in interpreting the results of this meta-analysis.\n                  <\/jats:p>","DOI":"10.1186\/s13052-026-02244-3","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:21:11Z","timestamp":1775816471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Active treatment vs. expectant management of patent ductus arteriosus in preterm infants: critical analysis of a meta-analysis"],"prefix":"10.1186","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1639-621X","authenticated-orcid":false,"given":"Carlo","family":"Dani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Agosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"de Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"2244_CR1","doi-asserted-by":"crossref","unstructured":"Buvaneswarran S, Wong YL, Liang S, Quek SC, Lee J. Active treatment vs expectant management of patent ductus arteriosus in preterm infants: a meta-analysis. JAMA Pediatr. 2025 May 27:e251025.","DOI":"10.1001\/jamapediatrics.2025.1025"},{"key":"2244_CR2","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1001\/jamapediatrics.2025.1022","volume":"179","author":"RI Clyman","year":"2025","unstructured":"Clyman RI. Early Treatment of the presymptomatic patent ductus arteriosus. JAMA Pediatr. 2025;179:818\u201320.","journal-title":"JAMA Pediatr"},{"key":"2244_CR3","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1056\/NEJMoa2207418","volume":"388","author":"T Hundscheid","year":"2023","unstructured":"Hundscheid T, OnlandW, Kooi EMW, et al. BeNeDuctus Trial investigators. expectant management or early ibuprofen for patent ductus arteriosus. N Engl J Med. 2023;388:980\u201390.","journal-title":"N Engl J Med"},{"key":"2244_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jpeds.2020.08.062","volume":"228","author":"K de Waal","year":"2021","unstructured":"de Waal K, Phad N, Stubbs M, Chen Y, Kluckow M. A randomized placebo-controlled pilot trial of early targeted nonsteroidal anti-inflammatory drugs in preterm infants with a patent ductus arteriosus. J Pediatr. 2021;228:82\u20136.","journal-title":"J Pediatr"},{"key":"2244_CR5","doi-asserted-by":"publisher","first-page":"105832","DOI":"10.1016\/j.earlhumdev.2023.105832","volume":"184","author":"A Smith","year":"2023","unstructured":"Smith A, Mullaly R, Franklin O, et al. Reproducibility of the EL-Khuffash PDA severity score and PDA diameter measurements in extremely preterm infants. Early Hum Dev. 2023;184:105832.","journal-title":"Early Hum Dev"},{"key":"2244_CR6","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00431-025-06485-y","volume":"184","author":"C Dani","year":"2025","unstructured":"Dani C, Sarcina D, Corsini I, Pratesi S, Poggi C, Montano S, Loi B, Regiroli G, De Luca D. Diagnosis of patent ductus arteriosus by different echocardiographic methods in very preterm infants. Eur J Pediatr. 2025;184:639.","journal-title":"Eur J Pediatr"},{"key":"2244_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jpeds.2020.12.008","volume":"233","author":"JC Roz\u00e9","year":"2021","unstructured":"Roz\u00e9 JC, Cambonie G, Le Thuaut A, et al. Effect of early targeted treatment of ductus arteriosus with ibuprofen on survival without cerebral palsy at 2 years in infants with extreme prematurity: a randomized clinical trial. J Pediatr. 2021;233:33\u201342.","journal-title":"J Pediatr"},{"issue":"2","key":"2244_CR8","doi-asserted-by":"publisher","first-page":"F99","DOI":"10.1136\/archdischild-2013-304695","volume":"99","author":"M Kluckow","year":"2014","unstructured":"Kluckow M, JefferyM, Gill A, Evans N. A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed. 2014;99(2):F99\u2013104.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"2244_CR9","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJMoa2305582","volume":"390","author":"S Gupta","year":"2024","unstructured":"Gupta S, Subhedar NV, Bell JL, et al. Baby-OSCAR Collaborative Group. Trial of selective early treatment of patent ductus arteriosus with ibuprofen. N Engl J Med. 2024;390:314\u201325.","journal-title":"N Engl J Med"},{"key":"2244_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jpeds.2020.10.024","volume":"229","author":"A El-Khuffash","year":"2021","unstructured":"El-Khuffash A, Bussmann N, Breatnach CR, Smith A, Tully E, Griffin J, et al. A pilot randomized controlled trial of early targeted patent ductus arteriosus treatment using a risk based severity score (The PDA RCT). J Pediatr. 2021;229:127\u201333.","journal-title":"J Pediatr"},{"key":"2244_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jpeds.2018.09.012","volume":"205","author":"RI Clyman","year":"2019","unstructured":"Clyman RI, Liebowitz M, Kaempf J, et al. PDA-TOLERATE (PDA: to leave it alone or respond and treat early) trial investigators. PDA-TOLERATE trial: an exploratory randomized controlled trial of treatment of moderate-to-large patent ductus arteriosus at 1 week of age. J Pediatr. 2019;205:41\u20138.","journal-title":"J Pediatr"},{"key":"2244_CR12","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jpeds.2011.12.031","volume":"160","author":"IR Sosenko","year":"2012","unstructured":"Sosenko IR, Fajardo MF, Claure N, Bancalari E. Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. J Pediatr. 2012;160:929\u201335.","journal-title":"J Pediatr"},{"key":"2244_CR13","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1001\/jamapediatrics.2020.1447","volume":"174","author":"SI Sung","year":"2020","unstructured":"Sung SI, Lee MH, Ahn SY, Chang YS. ParkWS. Effect of nonintervention vs oral ibuprofen in patent ductus arteriosus in preterm infants: a randomized clinical trial. JAMA Pediatr. 2020;174:755\u201363.","journal-title":"JAMA Pediatr"},{"key":"2244_CR14","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1055\/a-1782-5860","volume":"41","author":"S Potsiurko","year":"2024","unstructured":"Potsiurko S, Dobryanskyy D, Sekretar L, Salabay Z. Randomized noninferiority trial of expectant management versus early treatment of patent ductus arteriosus in preterm infants. AmJ Perinatol. 2024;41:730\u20138.","journal-title":"AmJ Perinatol"},{"key":"2244_CR15","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/cea.14085","volume":"52","author":"E Van Vogt","year":"2022","unstructured":"Van Vogt E, Cro S, Cornelius VR, et al. Individual participant data meta-analysis versus aggregate data meta-analysis: a case study in eczema and food allergy prevention. Clin Exp Allergy. 2022;52:628\u201345.","journal-title":"Clin Exp Allergy"},{"key":"2244_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.puhe.2018.08.015","volume":"165","author":"J Dailey","year":"2018","unstructured":"Dailey J, Rosman L, Silbergeld EK. Evaluating biological plausibility in supporting evidence for action through systematic reviews in public health. Public Health. 2018;165:48\u201357.","journal-title":"Public Health"},{"key":"2244_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/1469-0691.12494","volume":"20","author":"WG Melsen","year":"2014","unstructured":"Melsen WG, Bootsma MC, Rovers MM, Bonten MJ. The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses. Clin Microbiol Infect. 2014;20:123\u20139.","journal-title":"Clin Microbiol Infect"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-026-02244-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13052-026-02244-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-026-02244-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:45:37Z","timestamp":1781646337000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13052-026-02244-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2244"],"URL":"https:\/\/doi.org\/10.1186\/s13052-026-02244-3","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Prof. Carlo Dani received honoraria from Chiesi Farmaceutici SpA, Sanofi Italia, and Gepa Diagnostics for scientific consultancies. Other authors declare that there are no conflicts of interests. Prof. Carlo Dani is member of the Editorial Board of the Italian Journal of Pediatrics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}